ASMB - Assembly Biosciences, Inc.

Assembly Biosciences, Inc. , a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection.

As of May 15, 2026: spot at $28.84, ATM IV 73.2%, net GEX $7.2K.

Sector
Healthcare
Industry
Biotechnology
Market Cap
$504.1M
Beta
1.09
52-Week Range
12.19-39.71
CEO
Jason A. Okazaki
Employees
73
IPO Date
Dec 17, 2010
Exchange
NASDAQ

What ASMB Looks Like to Options Traders Today

IV rank of 14.9% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); positive net gamma exposure ($7.2K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (-0.371) prices puts richer than calls, the typical equity downside-protection skew.

What This Page Covers

The ASMB overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.

Frequently asked ASMB overview questions

What is ASMB?
ASMB is the ticker symbol for Assembly Biosciences, Inc., a listed security. Assembly Biosciences, Inc. , a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. Listed on NASDAQ. ASMB is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
What does the ASMB options snapshot look like today?
As of May 15, 2026, the ASMB options snapshot shows spot at $28.84, ATM IV 73.2%, IV rank 14.9%, net GEX $7.2K, expected move 20.99%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
What are ASMB's key statistics?
Assembly Biosciences, Inc. (ASMB) carries a market capitalization of $504.1M, beta of 1.09 relative to the broader market, 52-week range of 12.19-39.71. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
What sector or industry does ASMB belong to?
Assembly Biosciences, Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare ASMB's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
How current is the ASMB data on this page?
The options snapshot above is dated May 15, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).